Adjuvant chemotherapy containing oxaliplatin without radiotherapy to improve survival of local advanced low and middle rectal cancer.

Abstract

e14024 Background: In this study, the impact of oxaliplatin on survival of local advanced rectal cancer patients were analyzed by comparing the survival of patients accepted only radical surgery (group S) and patients accepted radical surgery following oxaliplatin-containing adjuvant chemotherapy (group SO). Methods: The data of patients, who accepted radical surgery in our center from Jan 2002 to Jun 2009, were reviewed. Inclusion criteria: carcinoma ≤12 cm from the anal verge; pathologically confirmed T3/4 or N1/2; without history of malignancy; neither transanal nor transsacral resection. Patients who accepted radiotherapy were excluded. The disease specific survival (DSS) and overall survival (OS) of patients in group S and SO were analyzed. Results: 236 patients were included in analysis (S 135 vs. SO 101), including 11 patients without survival information. The most of patients' basic characteristics were similar in two groups (P>0.05). However, the ratio of stage II patients in group S was higher than that in group SO (51.9% vs. 27.0%, P<0.001). The DSS of group SO were higher in patients with stage II, N1a or mucious adenocarcinoma than patients in group S (P<0.05). The OS of group SO were higher in patients with N1a, N2 or mucious adenocarcinoma than patients in group S (P<0.05). Conclusions: Adjuvant chemotherapy containing oxaliplatin improved survival of local advanced low and middle rectal cancer. Randomized perspective trials are needed to clarify the importance of oxaliplatin for rectal cancer. [Table: see text]